Social Media Ideas for Fesariustherapeutics

Fate’s off-the-shelf CAR-T therapy shows early promise in treatment-resistant autoimmune disease

“We were not expecting to see clinical responses so early,” Vaneet Sandhu, M.D., rheumatologist and vice president of clinical development at Fate Therapeutics, told Fierce.

Vera Therapeutics

Vera Therapeutics Anonymous (not verified) Wed, 07/01/2026 - 06:05 field_thread_url https://cafepharma.com/boards/threads/vera-therapeutics.713115/...

<![CDATA[FDA Issues CRL to Elevar Therpaeutics for Combination of Rivoceranib and Camrelizumab ]]>

<![CDATA[Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Ther...

FesariusTherapeutics Secures $20 Million for Dermal Repair Technology

The Series A funding will support the commercial expansion of a hydrogel template used in wound management and reconstructive surgery.

Travere Therapeutics: Filspari Is Becoming A Rare Kidney Disease Platform

<![CDATA[FDA Sends CRL to Cingulate for CTx-1301]]>

<![CDATA[Steer Bio Targets Lymphedema with Regenerative Cell Therapy Platform]]>

<![CDATA[Parabilis Medicines Raises $670 Million in Initial Public Offering ]]>

A PureTech startup banks $180M for a new IPF drug

Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.

<![CDATA[WHO Prioritizes Three Experimental Treatments for Bundibugyo Ebola Strain ]]>

Major Biopharmaceutical Company Files First-in-Human Trial Supported by PAK BioSolutions GMP Purification System

A major biopharmaceutical company has filed a First-in-Human (FIH) clinical trial application with drug product manufactured using the PAK BioSolutions system. The milestone demons...

Fulcrum scraps SCD program, considers options after FDA takes hard line on safety risks

Fulcrum Therapeutics has scrapped its sole clinical-stage program after the FDA took a hard line on the modality following the recent withdrawal of Ipsen’s Tazverik from the U.S. m...

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Subcutaneous Sarclisa Escena]]>

Merck’s anti-TL1A antibody from Prometheus buyout passes ph. 3 test in ulcerative colitis

Merck is making advances in the lucrative ulcerative colitis field with the key prize of its $11 billion buyout from several years ago.

ADC Therapeutics

ADC Therapeutics Anonymous (not verified) Sun, 06/07/2026 - 17:48 field_thread_url https://cafepharma.com/boards/threads/adc-therapeutics.665008/...

Verastem

Verastem Anonymous (not verified) Wed, 06/10/2026 - 20:50 field_thread_url https://cafepharma.com/boards/threads/verastem.708020/ board...

United Therapeutics pays $140M for thymic cell therapy startup

United Therapeutics has paid $140 million to buy Thymmune Therapeutics for preclinical regenerative cell therapies focused on the thymus.

SFM

SFM Anonymous (not verified) Wed, 06/10/2026 - 20:50 field_thread_url https://cafepharma.com/boards/threads/sfm.701491/ board name...

Vera Therapeutics’ First-in-Class Kidney Disease Drug Lands Speedy FDA Approval

FDA approval of Vera Therapeutics’ Trutakna makes it first in a new class of medicines designed to block two targets to treat immunoglobulin A nephropathy, an autoimmune disease th...

Novartis RNA Med From $12B Deal Keeps Building Case to Become First Therapy for Rare Muscle Disease

Novartis said its RNA therapy del-brax met goals of a Phase 1/2 study in facioscapulohumeral muscular dystrophy (FSHD), an inherited muscle disorder that currently has no FDA-appro...

Verastem

Verastem Anonymous (not verified) Fri, 06/19/2026 - 23:58 field_thread_url https://cafepharma.com/boards/threads/verastem.708020/ board...

<![CDATA[Pharmaceutical Executive Daily: FDA Issues CRL to Elevar Therapeutics]]>

Forte Biosciences: FB102 Is Becoming A Platform Story, Not A Single-Indication Bet